ライフサイエンスコーパス: poly-

1 ctive/Placebo) and sensitization level (Mono/Poly).

2 jugate, methoxy-poly (ethylene glycol)-block-poly (2-methyl-2-carboxyl-propylene carbonate-graft-SMAR

3 embly properties of the prepared amphiphilic poly[(2-methyl-2-oxazine)- grad-(2-butyl-2-oxazoline)] (

4 grad-PBuOx) as well as the thermoresponsive poly[(2-methyl-2-oxazine)- grad-(2-propyl-2-oxazoline)]

5 A new chelating resin, poly [2-(4-methoxyphenylamino)-2-oxoethyl methacrylate-c

6 -thiophene alternating donor copolymer named poly{[2,7-(5,5-didecyl-5H-1,8-dithia-as-indacenone)]-alt

7 Poly[{2,5-bis-(2-ethylhexyl)-3,6-bis-(thien-2-yl)-pyrrol

8 anoparticles (AuNPs) and Prussian blue (PB)- poly (3,4- ethylenedioxythiophene) (PEDOT)- AuNPs nanoco

9 nine entrapment within an electropolymerised poly (3,4-ethylendioxythiophene) (PEDOT) film were evalu

10 nanocomposite composed of conducting polymer poly (3,4-ethylenedioxythiophene) (PEDOT) doped with gra

11 ve pole side of the DMFC - with a conductive poly (3,4-ethylenedioxythiophene) (PEDOT) layer and a po

12 graphene oxide (GO) doped conducting polymer poly (3,4-ethylenedioxythiophene) (PEDOT) was prepared t

13 By combining Poly (3,4-ethylenedioxythiophene) (PEDOT), with Carbon N

14 of charge transfer between electrodeposited poly-(3-hexylthiophene) films and a model redox-active m

15 onucleotide (probe) on the Au nanoparticles- poly (4-aminothiophenol)/ reduced graphene oxide/glassy

16 carbon electrodes (W1 and W2) modified with poly (4-hydroxyphenylacetic acid).

17 Osmium tetroxide on poly (4-vinylpyridine) was used to wire the laccase for

18 ng of CAP with aptamer, immobilized onto the poly-(4-amino-3-hydroxynapthalene sulfonic acid) (p-AHNS

19 rmation for spin-coated semiconducting PTB7 (poly[[4,8-bis[(2-ethylhexyl)oxy]benzo[1,2-b:4,5-b']dithi

20 in blends of the polymer solar-cell material poly[[4,8-bis[(2-ethylhexyl)oxy]benzo[1,2-b:4,5-b']dithi

21 es are fabricated with these SHSAMs: ITO/IFL/poly[[4,8-bis[(2-ethylhexyl)oxy]benzo[1,2-b:4,5-b']dithi

22 hotophysics of organic solar cells employing poly[(5,6-difluoro-2,1,3-benzothiadiazol-4,7-diyl)-alt-(

23 grown on aluminum foil (VACNT-Al foil) with poly (9,9-di-(2-ethylhexyl)-fluorenyl-2,7-diyl)-end capp

24 Poly (9-(2-diallylaminoethyl)adenine HCl-co-sulfur dioxi

25 SBD) prepared from a semiconducting material poly-(9,9-dioctylfluorene) (F8).

26 near-infrared (NIR) dyes into the matrix of poly[(9,9-dioctylfluorene)-co-2,1,3-benzothiadiazole-co-

27 rst embedded the NIR dyes into the matrix of poly[(9,9-dioctylfluorene)-co-2,1,3-benzothiadiazole-co-

28 Trypanosomes possess two canonical RNA poly (A) polymerases (PAPs) termed PAP1 and PAP2.

29 hed for cell components and protein binding, poly (A) RNA binding and RNA binding were enriched for m

30 he first study to reveal that TATA boxes and poly (A) tails are direct targets for BBR in its regulat

31 esent study demonstrates that TATA boxes and poly (A) tails are the first and second primary targets

32 higher levels of expression by targeting the poly (A) tails of mRNAs.

33 ulatory regions as well as the poly adenine (poly (A)) tail at the mRNA terminus.

34 (NOT)," which catalyzes the removal of mRNA poly-(A) tails, the first obligatory step in mRNA decay.

35 Using public and proprietary poly-(A)(+) RNA-seq data as well as a collection of full

36 ttlebrush-like hydroxypropyl cellulose-graft-poly (acrylic acid) (HPC-g-PAA) as a template and was co

37 osite electrodes and polyvinyl alcohol (PVA)-poly (acrylic acid) (PAA) copolymer separator has been d

38 e iodine negativity, annexin positivity, and poly (adenosine 5'-diphosphate-ribose) polymerase cleava

39 8)F) fluorthanatrace (FTT) depicts activated poly (adenosine diphosphate-ribose)polymerase (PARP) exp

40 A phase II prospective clinical trial of the poly-(adenosine diphosphate-ribose) polymerase inhibitor

41 Here, the distribution of poly (ADP ribose) (PAR) was determined in CSB-deficient

42 In CSB-deficient cells, poly (ADP ribose) polymerase (PARP) is persistently acti

43 Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated stan

44 HR-deficient cancers are hypersensitive to Poly (ADP ribose)-polymerase (PARP) inhibitors, but can

45 We recently identified that poly (ADP) ribose glycohydrolase (PARG) is a strong cand

46 nt is mediated by the zinc finger domain and poly (ADP-ribose) (PAR).

47 f XRCC1 is required for selective binding to poly (ADP-ribose) at low levels of ADP-ribosylation, and

48 ssue, we have characterized the mechanism of poly (ADP-ribose) binding by XRCC1 and examined its impo

49 lly promoting stabilization of a new target, poly (ADP-ribose) glycohydrolase (PARG) mRNA, by binding

50 show that recombinant FUS binds directly to poly (ADP-ribose) in vitro, and that both GFP-tagged and

51 Poly (ADP-ribose) is synthesized at DNA single-strand br

52 emicals were tested for inhibitory effect of poly (ADP-ribose) polymerase (PARP) activity in vitro an

53 activation of caspase-8 and -3, cleavage of poly (ADP-Ribose) polymerase (PARP) and apoptosis.

54 Inhibitors against poly (ADP-ribose) polymerase (PARP) are promising target

55 ion of apoptotic cell death and detection of poly (ADP-ribose) polymerase (PARP) cleavage.

56 oded by PML-RARA) are extremely sensitive to poly (ADP-ribose) polymerase (PARP) inhibition, in part

57 Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) ol

58 Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), i

59 recent approval of olaparib (Lynparza), the poly (ADP-ribose) polymerase (PARP) inhibitor for treati

60 displayed synergistic cytotoxicity with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib a

61 The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib i

62 rminant that elicits therapeutic response to poly (ADP-Ribose) polymerase (PARP) inhibitor.

63 Poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib

64 (BRCA) mutations that confer sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis),

65 izes cancer cells to DNA damaging agents, to Poly (ADP-ribose) polymerase (PARP) inhibitors and cross

66 Poly (ADP-ribose) polymerase (PARP) inhibitors have emer

67 Poly (ADP-ribose) polymerase (PARP) inhibitors have emer

68 Targeted therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emer

69 Poly (ADP-ribose) polymerase (PARP) inhibitors have show

70 Poly (ADP-ribose) polymerase (PARP) inhibitors have show

71 atment with immune checkpoint inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors in a vari

72 ion (HR) and renders cells hypersensitive to poly (ADP-ribose) polymerase (PARP) inhibitors used to t

73 eclinical work, we found that combination of poly (ADP-ribose) polymerase (PARP) inhibitors with drug

74 ls is being targeted with platinum drugs and poly (ADP-ribose) polymerase (PARP) inhibitors.

75 HR deficient show a significant response to poly (ADP-ribose) polymerase (PARP) inhibitors; patients

76 Poly (ADP-ribose) polymerase (PARP) is the best-known el

77 Poly (ADP-ribose) polymerase (PARP) plays a significant

78 er an exquisite sensitivity to inhibitors of poly (ADP-ribose) polymerase (PARP) that are being teste

79 nd other molecular targets available such as poly (ADP-ribose) polymerase (PARP), epidermal growth fa

80 rs of the base excision repair (BER) protein poly (ADP-ribose) polymerase (PARP).

81 y protein BIM, cleaved caspase 3 and cleaved poly (ADP-ribose) polymerase (PARP).

82 005) concomitant with an increase in cleaved poly (ADP-ribose) polymerase 1 (P < 0.05), indicative of

83 Poly (ADP-ribose) polymerase 1 (PARP-1) is a constitutiv

84 Poly (ADP-ribose) polymerase 1 (PARP1) has emerged as an

85 Inhibition of beta-catenin, poly (ADP-ribose) polymerase 1 (PARP1), or enhancer of z

86 langiectasia mutated (ATM), but dependent on poly (ADP-ribose) polymerase 1 (PARP1), which ADP ribosy

87 lementing protein 1, DNA polymerase beta, or poly (ADP-ribose) polymerase 1 activity, all of which fa

88 -2, MCP-3, CXCL9, CXCL10, CXCL5, ENRAGE, and poly (ADP-ribose) polymerase 1.

89 reatly reduced or ablated by an inhibitor of poly (ADP-ribose) polymerase activity.

90 termined by Western blot analysis of cleaved poly (ADP-ribose) polymerase and caspase 3.

91 caspase-8, and caspase-9 activation and less poly (ADP-ribose) polymerase cleavage compared with WT l

92 downregulation of glucose transporter-1 and poly (ADP-ribose) polymerase cleavage while preserving t

93 pectively, and high selectivity toward other poly (ADP-ribose) polymerase enzymes.

94 a potential marker of long-term response to poly (ADP-ribose) polymerase inhibition and that restora

95 Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced v

96 reased sensitivity to ionizing radiation and poly (ADP-ribose) polymerase inhibition.

97 rpose Durable and long-term responses to the poly (ADP-ribose) polymerase inhibitor olaparib are obse

98 Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in

99 Ialpha inhibitor, L67, in combination with a poly (ADP-ribose) polymerase inhibitor.

100 Poly (ADP-ribose) polymerase inhibitors (PARPis) are cli

101 Poly (ADP-ribose) polymerase inhibitors combined with im

102 d treatments such as antiangiogenic drugs or poly (ADP-ribose) polymerase inhibitors offer potential

103 vic radiotherapy, or previous treatment with poly (ADP-ribose) polymerase inhibitors.

104 4K20me0 is required for HR and resistance to poly (ADP-ribose) polymerase inhibitors.

105 overexpression of caspase-3, higher cleaved poly (ADP-ribose) polymerase levels (p < 0.007), and a h

106 ian log-fold change (suppression) of cleaved poly (ADP-ribose) polymerase was greater with palbocicli

107 is, and activation of caspase-3, -7, -8, -9, poly (ADP-ribose) polymerase, and lamin A/C.

108 thodologies for studying robust responses of poly (ADP-ribose) polymerase-1 (PARP-1) to DNA damage wi

109 motes cytotoxicity in a process dependent on poly (ADP-ribose) polymerase-1 (PARP-1); a NAD(+)-consum

110 Poly (ADP-ribose) polymerase-1 (PARP1) is a highly conse

111 ent of targeted agents such as inhibitors of poly (ADP-ribose) polymerase-1 and mTOR and immunomodula

112 Purpose To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is

113 of UVA laser induced damage in cells lacking poly (ADP-ribose) polymerase-1.

114 Apoptosis was characterized by cleaved poly (ADP-ribose) polymerase.

115 tive cells and the cleavage of caspase-3 and poly (ADP-ribose) polymerase.

116 appears to involve the catalytic activity of poly (ADP-ribose) polymerase.

117 of their breakage, and to be antagonized by poly (ADP-ribose) polymerase/RECQ1-regulated restart.

118 Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PA

119 ys conserved in all eukaryotic cells include poly (ADP-ribose) polymerases (PARPs), sirtuins, AMP-act

120 ecently been suggested to be a target of the poly (ADP-ribose) polymerases Tankyrase 1, and we have f

121 es of sub-nuclear PCNA foci, suggesting that poly (ADP-ribose) promotes XRCC1 recruitment both at sin

122 These data support the hypothesis that poly (ADP-ribose) synthesis promotes XRCC1 recruitment a

123 nction of the DLK regeneration pathway, that poly-(ADP ribosylation) inhibits axon regeneration acros

124 their sensitivity to DNA damaging agents and poly-(ADP)-ribose polymerase inhibitors (PARPis).

125 rase 1 (PARP1) and the deribosylating enzyme poly-(ADP-ribose) glycohydrolase (PARG), which dynamical

126 vity of ATM-mutant cells to topotecan or the poly-(ADP-ribose) polymerase (PARP) inhibitor olaparib r

127 Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis)

128 Bax and Bak, and processing of caspases and poly-(ADP-ribose) polymerase (PARP-gamma).

129 iated by the nuclear ADP-ribosylating enzyme poly-(ADP-ribose) polymerase 1 (PARP1) and the deribosyl

130 Poly-(ADP-ribose) polymerase inhibitors (PARPi) selectiv

131 ocation from mitochondria to the nucleus and poly-(ADP-ribose)-polymerase (PARP) activation.

132 latinum-containing therapy and inhibitors of poly-(ADP-ribose)-polymerase (PARP)(14,15).

133 (POLQ [also referred to as POLtheta], RAD51, poly [ADP-ribose] glycohydrolase).

134 Poly [ADP-ribose] polymerase 1 (PARP-1) is a highly abun

135 sponse to oxidative stress via regulation of poly [ADP-ribose] polymerase 1 (PARP1).

136 -1) liposomes were used to deliver a PARP-1 (poly [ADP-ribose] polymerase 1) inhibitor: AZ7379.

137 afer"-like bilayer film of polyelectrolytes (Poly (allyl amine hydrochloride/poly(sodium 4-styrene su

138 isacrylamide-diaminohexane) (ABP)-conjugated poly (amidoamine) (PAMAM) dendrimer (PAM-ABP) in hMSCs.

139 bust procedure for synthesis of generation-4 poly-(amidoamine) (PAMAM) dendrimers with a precisely co

140 In order to visualise both Poly-, and Mono-, ADP-ribosylation in vivo, we engineere

141 utoantibodies can originate from the pool of poly- and autoreactive clones that populate the naive B

142 We found significantly higher frequencies of poly- and autoreactive new emigrant/transitional and mat

143 The poly- and autoreactive property is therefore not due to

144 emonstrate that bNAbs are significantly more poly- and autoreactive than nNAbs.

145 hat as a class, bNAbs are significantly more poly- and autoreactive than nNAbs.

146 The poly- and autoreactivity of bNAbs surely contribute to t

147 The strong association of poly- and autoreactivity with bNAbs, but not nNAbs from

148 (D)J mutation per se does not correlate with poly- and autoreactivity.

149 T-cell depletion, etc., alone does not cause poly- and autoreactivity.

150 fCS poly- and oligosaccharides display low cytotoxicity in v

151 In conclusion, neutral poly- and oligosaccharides from H. suaveolens have a pre

152 olation, and complete structural analysis of poly- and oligosaccharides of Shigella sonnei phase II E

153 Increasing levels of poly- and perfluorinated alkyl substances (PFASs) have r

154 of atmospheric versus oceanic transport for poly- and perfluorinated alkyl substances (PFASs) reachi

155 FFs) has resulted in hot spots polluted with poly- and perfluorinated alkyl substances (PFASs).

156 describe here an efficient defluorination of poly- and perfluorinated aromatics under oxidative condi

157 Perfluorooctanoic acid (PFOA) is a poly- and perfluoroalkyl substance (PFAS) associated wit

158 Transport of poly- and perfluoroalkyl substances (PFAS) at aqueous fi

159 was used to rapidly and effectively degrade poly- and perfluoroalkyl substances (PFAS) from liquid i

160 ated pollutants (POPs), while the effects of poly- and perfluoroalkyl substances (PFAS) have been poo

161 Between 2013 and 2015, concentrations of poly- and perfluoroalkyl substances (PFAS) in public dri

162 ocean is thought to be the terminal sink for poly- and perfluoroalkyl substances (PFAS) that have bee

163 periments were performed to assess uptake of poly- and perfluoroalkyl substances (PFAS), both single

164 ated biphenyls (PCBs) and protein-associated poly- and perfluoroalkyl substances (PFASs) and mercury

165 y of consumer products that are treated with poly- and perfluoroalkyl substances (PFASs) and related

166 led fires has led to the co-contamination of poly- and perfluoroalkyl substances (PFASs) and trichlor

167 Growing evidence that certain poly- and perfluoroalkyl substances (PFASs) are associat

168 Poly- and perfluoroalkyl substances (PFASs) are persiste

169 Poly- and perfluoroalkyl substances (PFASs) derived from

170 Poly- and perfluoroalkyl substances (PFASs) have been de

171 is limited knowledge on the distribution of poly- and perfluoroalkyl substances (PFASs) in different

172 ata on predictors of gestational exposure to poly- and perfluoroalkyl substances (PFASs) in the Unite

173 the unique ability to completely mineralize poly- and perfluoroalkyl substances (PFASs) through pote

174 ontributes considerably to human exposure to poly- and perfluoroalkyl substances (PFASs).

175 list of anionic, zwitterionic, and cationic poly- and perfluoroalkyl substances (PFASs).

176 biodegradation in subsurface locations where poly- and perfluoroalkyl substances occur with hydrocarb

177 Polybrominated diphenyl ethers (PBDEs) and poly- and perfluoroalkylated substances (PFASs) were fou

178 These data suggest that poly- and self-reactive germline antibodies such as TLF2

179 y electropolymerization a conductive polymer poly-(aniline-co-3-aminobenzoic acid) (PANABA) then we i

180 of chevron-type GNRs (cGNRs) templated by a poly-(arylene ethynylene) precursor prepared through rin

181 chondrocytes via electroporation followed by poly (beta-amino esters) (PBAE) transfection.

182 were atypical lipoteichoic acids (LTAs) with poly-(beta1->4)-ManNAc backbones substituted with phosph

183 Poly (butylene adipate-co-terephthalate) (PBAT) nanocaps

184 of poly(l-lactide) and poly ethylene glycol/poly(-caprolactone), allowing diffusion-controlled relea

185 Poly-(CUG) binding proteins in the Muscleblind-like (MBN

186 polymeric non-viral vector Arginine-grafted poly (cystaminebisacrylamide-diaminohexane) (ABP)-conjug

187 ulina sp. LEB 18 by nanoprecipitation, using poly (d)(,)(l)(-)lactic acid (PLA)/poly (d)(,)(l)(-)lact

188 on, using poly (d)(,)(l)(-)lactic acid (PLA)/poly (d)(,)(l)(-)lactic-co-glycolic acid (PLGA) (75:25 w

189 Poly (d,l-lactide co-glycolide, PLGA)-based NPs loaded w

190 indings demonstrate that the prevascularized poly (D,L-lactide-co-epsilon-caprolactone) scaffold main

191 rized, subcutaneously implanted, retrievable poly (D,L-lactide-co-epsilon-caprolactone) scaffold.

192 ery system, PTX was covalently conjugated to poly (D,L-lactide-co-glycolide) polymeric core by redox-

193 using BVDV E2 and NS3 proteins formulated in poly-(D, L-lactic-co-glycolic acid) (PLGA) nanoparticles

194 optimal production of IFN-beta triggered by poly (dA:dT) or HSV-1 requires IFNAR signaling.

195 ays, it was found that a Pluronic F68 coated poly (decanediol-phenylsuccinate-co-succinate) stimulate

196 alladium nanoparticles were in-situ grown on poly (diallyldimethylammonium chloride) functionalized b

197 as studied using 5 mum tall line patterns of poly (dimethylsiloxane) (PDMS).

198 the development of a novel L-cysteine-based poly (disulfide amide) (Cys-PDSA) family for fabricating

199 oteins based on the self-healing capacity of poly (DL)-lactic-co-glycolic acid (PLGA) microspheres co

200 Poly (dl-lactide-co-glycolide) (PLGA) nanoparticles of a

201 In this study, we fabricate grid poly (epsilon-caprolactone)-poly (ethylene glycol) micro

202 Self-healing poly (ethylene co-methacrylic acid) ionomers (EMAA) are

203 a the self-assembly of diblock copolymers of poly (ethylene glycol) (PEG) and poly (propylene sulfide

204 We present unexpected evidence that a poly (ethylene glycol) (PEG)-lipid conjugate enables cho

205 noparticles (NPs) made of poly (lactic acid) poly (ethylene glycol) block copolymer (PLA-PEG), and th

206 aaPEG) introducing an acetic acid terminated poly (ethylene glycol) methyl ether (aaPEG) onto the Thr

207 e fabricate grid poly (epsilon-caprolactone)-poly (ethylene glycol) microfibrous scaffold and infuse

208 -OH, and its polymer-drug conjugate, methoxy-poly (ethylene glycol)-block-poly (2-methyl-2-carboxyl-p

209 ed ICG-NH2 to the pendant carboxyl groups of poly (ethylene glycol)-block-poly(2-methyl-2-carboxyl-pr

210 od using capture antibody immobilized porous poly (ethylene) glycol diacrylate (PEGDA) hydrogel micro

211 senchymal stem cells (hMSCs) in a 3D printed poly-(ethylene glycol)-diacrylate (PEG-DA) hydrogel scaf

212 t a chemically functionalized conical shaped poly-(ethylene terephthalate) nanopore (PET nanopore) as

213 r, was complexed with biodegradable polymer (poly (ethyleneimine)-conjugated poly(CBA-DAH); PCDP), ge

214 obtained from porcine carotid arteries with poly (ethylmethacrylate-co-diethylaminoethylacrylate) (8

215 a non-GGGGCC RNA sequence revealed that both poly-(glycine-arginine) and poly-(proline-arginine) prot

216 antibodies, which then capture streptavidin-poly [horse radish peroxidase] (Poly-HRP).

217 ed dendritic cells (MoDCs) were treated with poly (I: C) of TLR3 ligand and imiquimod of TLR7 ligand,

218 tion antibody were significantly enhanced in poly (I: C), imiquimod along with inactivated PRRSV grou

219 The TLR3 agonist poly (I:C) activated TLR3 pathway and inhibited tumor ce

220 n barrier repair genes, that the TLR3 ligand Poly (I:C) also induced expression and function of tight

221 1 in microglia activation to protect against poly (I:C) imparted neuropathology and altered behavior

222 activation in hematopoietic cells induced by poly (I:C) injection, all Mx1-CreCbfb+/56M mice develope

223 cells did not re-appear until 96 hours post poly (I:C) injury.

224 e acinar and progenitor cells, 24 hours post poly (I:C) introduction.

225 preparation of Saccharomyces cerevisiae, or poly (I:C) was coated on a microneedle with inactivated

226 l in which polyinosinic: polycytidylic acid (poly (I:C)) was injected into pregnant mice.

227 ed (ds) RNA polyinosinic-polycytidylic acid (poly (I:C)) widely, but transiently, depleted the acinar

228 SMG recovery from the transient, but severe poly (I:C)-mediated injury and cellular depletion.

229 hallenged with Pam3Cys and LPS, but not with Poly (I:C).

230 en and two adjuvants, a double-stranded RNA (Poly (inosinic:cytidylic acid) (PolyI:C)) and an amphiph

231 ranules made of cyanophycin [multi-L-arginyl-poly (L-aspartic acid)], which is synthesized by cyanoph

232 Novel nano-biocomposite films based on poly (lactic acid) (PLA) were prepared by incorporating

233 ntly loaded into nanoparticles (NPs) made of poly (lactic acid) poly (ethylene glycol) block copolyme

234 of methoxy poly(ethylene glycol)(2000)-block-poly (lactic acid)(1800) (mPEG(2000)-b-PLA(1800)) and (m

235 polycaprolactone (PCL) (core layer), a 50:50 poly (lactic-co-glycolic acid) (PLGA) (sheath layer) and

236 polymer hybrid nanoparticles (CSLPHNPs) with poly (lactic-co-glycolic acid) (PLGA) core and lipid lay

237 ChABC into lipid microtubes and NEP1-40 into poly (lactic-co-glycolic acid) (PLGA) microspheres, obvi

238 last growth factor were entrapped within the poly (lactic-co-glycolic acid) (PLGA) nanoparticle, whic

239 radable materials, including the widely used poly (lactic-co-glycolic acid) (PLGA) nanoparticles cont

240 We examined this hypothesis by assembling poly (lactic-co-glycolic acid) (PLGA) particles loaded w

241 Poly (lactic-co-glycolic acid) (PLGA) supplies lactate t

242 Biodegradable polymers such as poly (lactic-co-glycolic acid) and polycaprolactone have

243 se antimiR-21) encapsulated in biodegradable poly (lactic-co-glycolic acid) nanoparticles (PLGA-NP),

244 mbrane damage as compared to similarly sized poly (lactic-co-glycolic acid) particles.

245 Biocompatible poly (lactic-co-glycolic acid) was selected as the polym

246 To overcome this limitation, electrospun poly (lactic-co-glycolide) (PLGA) mats, which have excel

247 Poly (lactide-co-glycolide) (PLGA) has been used for mak

248 Various ratios of cryo-ground poly (lactide-co-glycolide) (PLGA) nanofibres (CPN) were

249 ization of a cationic amphiphilic copolymer, poly (lactide-co-glycolide)-graft-polyethylenimine (PgP)

250 n expresses sense and antisense tetrapeptide poly-(LPAC) and poly-(QAGR) RAN proteins, respectively.

251 As poly (methyl methacrylate) (PMMA) remains the main mater

252 Easily accessible poly (methyl methacrylate) (PMMA), polyethylene terephth

253 Herein, a photothermally responsive poly (methyl methacrylate) (PMMA)/paper hybrid disk (PT-

254 The array was suitably interfaced with a poly- (methyl methacrylate) (PMMA) well-containing holde

255 s hybrid poly-(o-phenylene ethynylene)-block-poly-(methyl acrylate) block copolymers.

256 ower critical solution temperature (LCST) of poly( N-isopropylacrylamide) (PNiPAM) for a fixed concen

257 semiflexible polymers with thermoresponsive poly( N-isopropylacrylamide) (PNIPAM) produces internal

258 how here for the first time that short chain poly( N-isopropylacrylamide) (PNIPAM), one of the most f

259 rane was fabricated with hybrid materials of poly (N-isopropylacrylamide), (PNIPAM) within polytetraf

260 terface by coating the Li metal surface with poly((N-2,2-dimethyl-1,3-dioxolane-4-methyl)-5-norbornen

261 biomolecules present in saliva by brushes of poly[(N-(2-hydroxypropyl) methacrylamide)-co-(carboxybet

262 g a novel biointerface architecture based on poly[(N-(2-hydroxypropyl) methacrylamide)-co-(carboxybet

263 f the kinetic nature in the formation of the poly-[n]-catenane by the analysis of the packing energy

264 n successfully applied in the synthesis of a poly-[n]-catenane composed of interlocked M(12)L(8) icos

265 perties of such a heavily n-dopable polymer, poly{[N,N'-bis(2-octyldodecyl)-1,4,5,8-naphthalenedicarb

266 hose of the corresponding backbone-insulated poly{[N,N'-bis(2-octyldodecyl)-1,4,5,8-naphthalenedicarb

267 arity and the charge transport properties of poly{[N,N'-bis(2-octyldodecyl)-1,4,5,8-naphthalenediimid

268 yl)thiophene)] (PTPD3T) and acceptor polymer poly{[N,N'-bis(2-octyldodecyl)naphthalene-1,4,5,8-bis(di

269 echanochemically transformed into conjugated poly( o-phenylene-hexatrienylene) by sonication, with de

270 -transfer processes, giving access to linear poly-(o-phenylene ethynylene) with narrow molecular weig

271 ollowed by RAFT polymerization yields hybrid poly-(o-phenylene ethynylene)-block-poly-(methyl acrylat

272 tionally symmetric charged block copolymers, poly[(oligo(ethylene glycol) methyl ether methacrylate-c

273 n the polymer poly(propylene sulfide)(135)-b-poly[(oligoethylene glycol)(9) methyl ether acrylate](17

274 Infrequent poly- or autoreactivity among nNAbs implies that their d

275 Abs) has been performed to determine whether poly- or autoreactivity in bNAbs is a consequence of chr

276 ich were tested for both binding to AQP4 and poly- or autoreactivity.

277 r synthesizing both mono- and di-, tri-, and poly( p-carboxyphenyl)siloxanes with p-carboxyphenyl gro

278 High-performance fibers made of poly-(p-phenylene terephthalamide) (PPTA) with high stif

279 Poly (polyethylene glycol citrate-co-N-isopropylacrylami

280 After bypass of 8-oxoG by TLS PolY, products accumulate at the template position three

281 vealed that both poly-(glycine-arginine) and poly-(proline-arginine) proteins caused neurodegeneratio

282 polymers of poly (ethylene glycol) (PEG) and poly (propylene sulfide) (PPS) and use them for Rg3 enca

283 s used to synthesize an ABC triblock polymer poly[(propylenesulfide)-block-(N,N-dimethylacrylamide)-b

284 y all [PSI+] prion variants require inositol poly-/pyrophosphates for their propagation, and at least

285 of magnetic nanoparticles (MNPs) coated with poly (pyrrole-co-pyrrole-2-carboxylic acid) (Py/Py-COOH/

286 this study, we report on the combination of poly [pyrrole-co-3-carboxyl-pyrrole] copolymer and aptam

287 eraction on the intrinsic conjugation of the poly [pyrrole-co-3-carboxyl-pyrrole] copolymer and subse

288 e and antisense tetrapeptide poly-(LPAC) and poly-(QAGR) RAN proteins, respectively.

289 se that degrades the carbon storage molecule poly((R)-3-hydroxybutyrate) (PHB).

290 ophycin with an emphasis on the synthesis of poly[(R)-3-hydroxybutyrate] (PHB), a renewable biodegrad

291 llyldimethylammonium chloride) (PDADMAC) and poly (sodium 4-styrenesulfonate) (PSS) resulted in a dec

292 ucture ensemble of the tandem di-domain of a poly (U) binding protein.

293 ucleobase bias with a preference for binding poly (U) or d(T) while d(A) polymers bind with low affin

294 Notably, both saturated and (poly-)unsaturated FFAs are detected sensitively in the p

295 cost magnetic multi-walled carbon nanotubes-poly (vinyl alcohol) cryogel-micro-solid phase extractio

296 at husks were used to produce hydrogels with poly (vinyl alcohol).

297 rospun following electrospinning of Chitosan/poly-(vinyl alcohol) to form a bilayered wound patch.

298 Alginate/poly-(vinyl alcohol) was electrospun following electrosp

299 of a relaxor ferroelectric terpolymer, i.e., poly (vinylidene fluoride-trifluoroethylene-chlorofluoro

300 The model polymer was poly (vinylpyrrolidone-co-vinyl acetate) (PVPVA).